Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Black Hawk Acquisition Corporation Class A ( (BKHA) ) has issued an announcement.
On March 17, 2026, Vesicor Therapeutics, the proposed de‑SPAC target of Black Hawk Acquisition Corporation, appointed veteran biotech executive and retinal surgeon Michael Tolentino, M.D., as chief executive officer, with founder Luo Feng, Ph.D., moving into the role of chief scientific officer. The leadership transition is structured under a three‑year employment agreement that includes a modest base salary, performance‑based bonus discretion, severance protections, and non‑compete and confidentiality provisions.
The appointment brings to Vesicor a high‑profile figure with a track record in anti‑VEGF drug discovery, RNA interference therapeutics and AI‑driven drug development, including key roles in the origin of Avastin, Bevasiranib, and multiple venture‑backed biotech platforms. For Black Hawk and its investors, the move signals an effort to strengthen Vesicor’s management bench and industry relationships as the companies work toward completing their de‑SPAC merger and advancing Vesicor’s p53‑based cancer program through IND‑enabling studies and toward a planned regulatory filing.
More about Black Hawk Acquisition Corporation Class A
Black Hawk Acquisition Corporation is a special purpose acquisition company listed on Nasdaq that is pursuing a business combination with Vesicor Therapeutics, an early-stage biotechnology firm based in San Gabriel, California. Vesicor focuses on developing p53-based cancer therapeutics delivered through precision-engineered microvesicles, targeting advanced oncology indications with novel delivery platforms.
Vesicor operates in the highly competitive biotech sector, concentrating on preclinical and IND-enabling work rather than commercialized products. Its strategy centers on advancing a sole product candidate through the U.S. regulatory pathway, leveraging external contract research and pharma relationships to progress toward first-in-human studies and eventual FDA submissions.
Average Trading Volume: 3,284
Technical Sentiment Signal: Strong Buy
Find detailed analytics on BKHA stock on TipRanks’ Stock Analysis page.